Aspire Biopharma Holdings, Inc. (ASBP)
Nasdaq: ASBP · Pharmaceutical Preparations · Estero, FL · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 30, 2026 | Apr 7, 2025 | Mar 11, 2024 | Mar 21, 2023 |
| Revenue | 6,202 | · | · | · |
| Cost of revenue | 6,318 | · | · | · |
| Gross profit | -116 | · | · | · |
| Research and development | 923,914 | 144,356 | · | · |
| Sales and marketing | 789,829 | 126,094 | · | · |
| General and administrative | 17,637,432 | 940,421r | 1,340,168 | 976,345 |
| Total operating expenses | 19,351,175 | 1,210,871r | 1,340,168 | 976,345 |
| Operating income | -19,351,291 | -1,210,871 | · | · |
| Interest expense | 8,531,275 | 97,988 | 8,966 | · |
| Interest and investment income | · | 548,676 | 5,813,213 | 4,316,583 |
| Total non-operating income (expense) | -5,129,557 | -97,988r | 5,804,247 | 4,316,583 |
| Income before income taxes | -24,480,848 | -1,308,859 | · | · |
| Income tax expense | · | 1,013 | · | · |
| Net income including non-controlling interests | · | · | 4,464,079 | 3,340,238 |
| Net income | -24,480,848 | -1,309,872r | 4,464,079 | 3,340,238 |
| Earnings per share, diluted | -16.38 | -1.90 | · | · |
| Weighted average shares, basic | 1,494,956 | 689,913 | · | · |
| Weighted average shares, diluted | 1,494,956 | 689,913 | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseDebtInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding